Vigam-S, a solvent/detergent-treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura

Transfusion Medicine

Volumn 11, Issue 1, 2001, Pages 37-44

  Newland, A C ^a,d   Burton, I ^a   Cavenagh, J D ^a   Copplestone, A ^a   Dolan, G ^b   Houghton, J ^a   Reilly, T ^c  

^a Royal London ^*  (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Idiopathic thrombocytopenic purpura; Intravenous immunoglobulins; Safety; Solvent detergent

Indexed keywords

CORTICOSTEROID; DETERGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; SOLVENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MIDDLE AGED; MULTICENTER STUDY; REFERENCE VALUE; SPLENECTOMY; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; DETERGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REFERENCE VALUES; SOLVENTS; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035124062     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.2001.00281.x     Document Type: Article

References (21)

1. Barandun, S. (1985) Immunoglobulins. history, present trends and safety aspects. In: Intravenous Immunoglobulins in Immunodeficiency Syndromes and Idiopathic Thrombocytopenic Purpura (eds Waters, A.H., Webster, A.D.), 3-10. Royal Society of Medicine, London.
2. Blanchette, V.S., Freeman. J. & Garvey, B. (1998) Management of chronic immune thrombocytopenic purpura in children and adults. Seminars in Haematology, 35, (Suppl. 1), 36-51.
3. Bleeker, W.K., Agterberg, J., Rigter, G., de Vries-van Rossen, A. & Bakker, J.C. (1987) An animal model for the detection of hypotensive side-effects of an immunoglobulin press. Vox Sanguinis, 52, 281.
4. Bussel, J.B. & Pham, L.C. (1987) Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: Review of the literature. Vox Sanguinis, 52, 206-211.
5. Chidwick, K., Matejschuk, P., Gascoigne, E., Briggs, N., More, J.E. & Dash, C.H. (1999) Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects. Vox Sanguinis, 77, 204-209.
6. CPMP. (1997) Note for guidance on core SPC for human normal immunoglobulin (I.V.). CPMP/BPWP/859/95. EMEA, London (10 March).
7. Eden, O.B. & Lilleyman, J.S. (1992) Guidelines for the management of idiopathic thrombocytopenic purpura. Archives of Diseases in Childhood, 67, 1056-1058.
8. Ellie, E., Combe, C. & Ferrer, X. (1992) High-dose intravenous immune globulin and acute renal failure. New England Journal of Medicine, 327, 1032-1033.
9. European Pharmacopoeia. (1994) Human normal immunoglobulin for intravenous administration. Monograph, 918.
10. Gascoigne, E.W., Dash, C.H., Sutton, J.A., Mould, G. & Riches, P. (1996) The pharmacokinetics of immunoglobulin G after intravenous infusion: a comparison of two preparations. British Journal of Clinical Research, 7, 33-42.
11. Gascoigne, E.W., Leonard, G.A., Hartigan, K.J. & Dash, C.H. (1999) Safety and efficacy of an intravenous immunoglobulin (Vigam-S) in primary antibody deficiency: an interim report. Journal of Clinical Immunology, 90, 461.
12. George, J.N., El-Harake, M.A. & Raskob, G.E. (1994) Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 331, 1207-1211.
13. Godeau, B., Lesage, S., Divine, M., Wirquin, V., Farcet, J.P. & Bierling, P. (1993) Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood, 82, 1415-1421.
14. Horowitz, B., Prince, A.M., Hamman, J. & Watklevicz, C. (1994) Viral safety of solvent/detergent-treated blood products. Blood Coagulation and Fibrinolysis, 5, S21-S28.
15. Imbach, P.A. (1995) Immune thrombocytopenic purpura. In: Intravenous Immunoglobulin Therapy; Clinical Benefits and Future Prospects (ed. Kazatchkine, M.D.), 8, 43-46. The Parthenon Publishing Group, New York.
16. Imholz, B., Imbach, P., Baumgartner, C., Berchtold, W., Gaedicke, G., Gugler, E., Hirt, A., Hitzig, W., Mueller-Eckhardt, C. & Wagner, H.P. (1988) Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study. Blut, 56, 63-68.
17. Misbah, S. (1996) Products with low IgA content may be used in patients with total IgA deficiency. British Medical Journal, 313, 1400.
18. Newland, A.C. (1986) Intravenous immunoglobulin therapy in chronic idiopathic thrombocytopenic purpura. In: Clinical Use of Intravenous Immunoglobulins (eds Morell, A., Nydegger, V.E.), 203-214. Academic Press, London.
19. Ratko, T.A., Burnett, D.A., Foulke, G.E., Matuszewski, K.A. & Sacher, R.A. (1995) Recommendations for off-label use of intravenously administered immunoglobulin preparation. JAMA, 273, 1865-1870.
20. Schifferli, J., Leski, M., Favre, H., Imbach, P., Nydegger, U. & Davies, K. (1991) High-dose intravenous IgG treatment and renal function. Lancet, 337, 457-458.
21. Sekul, E.A. & Cupler, E.J. & Dalakas, M.C. (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Annals of Internal Medicine, 121, 259-262.